July 8, 2021 7:31 PM
Sanofi SA and GlaxoSmithKline Plc receive approval from Indian authorities for late-stage clinical trial of protein-based COVID-19 vaccine candidate
Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said today.<br />'' <br />''France's Sanofi and Britain's GSK in May kicked off global trials to include more than 35,000 adults to test the shot. They hope to get approvals by the end of 2021 after early-stage results showed the vaccine produces a robust immune response.<br />''&...